Long-term prospective study of the effect of ursodeoxycholic acid on cystic fibrosis-related liver disease

Journal of Clinical Gastroenterology

Volumn 32, Issue 4, 2001, Pages 324-328

  Nousia Arvanitakis, Sanda ^a,b   Fotoulaki, Maria ^a   Economou, Hippolyti ^a   Xefteri, Mairy ^a   Galli Tsinopoulou, Assimina ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b NONE   (Greece)

Author keywords

Cystic fibrosis; Cystic fibrosis related liver disease; Focal biliary cirrhosis; Nodular biliary cirrhosis; Ursodeoxycholic acid

Indexed keywords

URSODEOXYCHOLIC ACID;

ADOLESCENT; ADULT; ARTICLE; BILIARY CIRRHOSIS; CHILD; CYSTIC FIBROSIS; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; ECHOGRAPHY; FEMALE; FOLLOW UP; HEPATOSPLENOMEGALY; HUMAN; LIVER DISEASE; LIVER FUNCTION TEST; LIVER SCINTISCANNING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CHOLAGOGUES AND CHOLERETICS; CYSTIC FIBROSIS; FEMALE; HUMANS; LIVER DISEASES; LIVER FUNCTION TESTS; LONGITUDINAL STUDIES; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 0035079090     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200104000-00009     Document Type: Article

References (39)

1. Identification of the cystic fibrosis gene: Genetic analysis
2. Expression and characterization of the cystic fibrosis transmembrane conductance regulator
3. Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells
4. Cystic fibrosis: Gastrointestinal and hepatic complications and their management
5. Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group
6. Clinical and genetic risk factors for cystic fibrosis-related liver diseases
7. Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor
8. The major histocompatibility complex influences the development of chronic liver disease in male children and young adults with cystic fibrosis
9. Assessment of hepatobiliary involvement by ultrasound scanning in cystic fibrosis
10. Hepatoprotective properties of ursodeoxycholic acid
11. Molecular aspects of membrane stabilization by ursodeoxycholate
12. Effects of ursodeoxycholic acid and chenodeoxycholic acid on major histocompatibility complex class I gene expression
13. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis
14. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis
15. Effects of ursodeoxycholic acid on liver function in patients with cystic fibrosis and chronic cholestasis
16. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease
17. Early detection and therapy of biliary cirrhosis in cystic fibrosis
18. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: A double blind multicenter trial
19. Liver involvement in cystic fibrosis
20. An ultrasound scoring system for the diagnosis of liver disease in cystic fibrosis
21. Gastrointestinal manifestations of cystic fibrosis: Radiologic- pathologic correlation
22. The role of hepatobiliary, scintigraphy in cystic fibrosis
23. Hepatobiliary scintigraphy in children
24. Multifocal uptake of Tc-99m membrofenin in dilated liver ductules in a patient with cystic fibrosis
25. Liver disease in children with cystic fibrosis: US-biochemical comparison in 195 patients
26. Liver disease in cystic fibrosis
27. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease
28. Present and future treatment modalities for gastrointestinal diseases in cystic fibrosis
29. Correction of the cystic fibrosis defect by gene complementation in human intrahepatic biliary epithelial cell lines
30. Ursodeoxycholic acid in the treatment of liver diseases
31. Sustained biochemical and histological remission of primary biliary cirrhosis in response to medical treatment
32. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: A randomized, double blind study controlled with placebo
33. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis
34. Effect of ursodeoxycholic acid therapy on hepatic function in children with intrahepatic cholestatic liver disease
35. Ursodeoxycholic acid improves cholestasis in infants with cystic fibrosis
36. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis
37. Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up
38. Liver transplantation for hepatic cirrhosis in cystic fibrosis
39. Heart-lung-liver transplantation